Shopping Cart
- Remove All
Your shopping cart is currently empty
MRE-269
MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary arterial hypertension. MRE-269(ACT-333679) is an active metabolite of Selexipag (S253150).
Catalog No. T3S2007Cas No. 475085-57-5
Select Batch
Purity:99.57%
Contact us for more batch information
MRE-269
Catalog No. T3S2007Alias MRE269, MRE 269, ACT-333679Cas No. 475085-57-5
MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary arterial hypertension. MRE-269(ACT-333679) is an active metabolite of Selexipag (S253150).
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $29 | In Stock | |
| 10 mg | $53 | In Stock | |
| 25 mg | $86 | In Stock | |
| 50 mg | $118 | In Stock | |
| 100 mg | $198 | In Stock | |
| 200 mg | $293 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "MRE-269"
Rutin
Cited
Quercetin 3-O-rutinoside, Rutoside
T0795153-18-4
Rutin (Quercetin 3-O-rutinoside), a flavonoid, has a variety of biological activities including antiallergic, anti-inflammatory, antiproliferative, and anticarcinogenic properties.
- $36
Size
QTY
CitedTranilast Cited
MK 341, SB 252218
T269053902-12-8
Tranilast (SB 252218), an antiallergic drug, suppresses lipid mediator and cytokine release from inflammatory cells, therefore utilized in the treatment of allergic disorders.
- $36
Size
QTY
CitedRebamipide
Proamipide, OPC12759
T156290098-04-7
Rebamipide (OPC12759) is a quinolinone derivative with anti-ulcer and anti-inflammatory activities. Rebamipide induces cyclooxygenase 2 (COX2) synthesis which results in an increase in endogenous prostaglandin synthesis in the gastric mucosa. This agent also inhibits H. pylori-induced production of tumor necrosis factor (TNF) alpha and subsequent inflammation of the gastric mucosa. In addition, rebamipide scavenges oxygen-derived free radicals that potentially cause mucosal injury, and stimulates prostaglandin EP4 receptor gene expression followed by mucous secretion, thereby enhancing the gastric mucosal defense.
- $45
Size
QTY
Ethamsylate
Cyclonamine, Etamsylate, Dicynene, Aglumin
T00022624-44-4
Ethamsylate (Dicynene) usually is used as a hemostatic drug, which increases capillary endothelial resistance and platelet adhesion, and inhibits biosynthesis and action of prostaglandins.
- $30
Size
QTY
Pranoprofen
Pyranoprofen
T015952549-17-4
Pranoprofen (Pyranoprofen) (INN) is a non-steroidal anti-inflammatory drug used in ophthalmology.
- $35
Size
QTY
Ozagrel
OKY-046, Domenan
T623682571-53-7
Ozagrel (Domenan) is a selective thromboxane A(2) (TXA(2)) synthetase inhibitor with IC50 of 11 nM for rabbit platelet, used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.
- $32
Size
QTY
Angoroside C
T3903115909-22-3
Angoroside C is a Potential anti-inflammatory compound. Inhibitor of prostaglandin E2 release in mouse peritoneal macrophages in vitro. Shows potent antioxidative activity in reducing the oxidized OH adducts of dAMP and dGMP. Reveals some trypanocidal potential.
- $30
Size
QTY
p-Hydroxycinnamic acid
p-Coumaric acid, p-Cumaric acid, p-Hydroxy-cinnamic acid, NSC 59260
T70537400-08-0
p-Hydroxycinnamic acid (NSC-59260) can inhibit platelet activity, with IC50s of 371 μM, 126 μM for thromboxane B2 production and lipopolysaccharide-induced prostaglandin E2 generation, respectively.
- $29
Size
QTY
Evodiamine
d-Evodiamine, Isoevodiamine, (+)-Evodiamine
T2868518-17-2
Evodiamine (d-Evodiamine) is an alkaloid isolated from the fruit of daylily and has a variety of biological activities including anti-inflammatory, anti-obesity and anti-tumor.
- $42
Size
QTY
Tebufelone
T68155112018-00-5In house
Tebufelone is a potent in vitro inhibitor of CO , a novel non-steroidal anti-inflammatory drug (NSAID) belonging to the di-tert-butylphenol (DTBP) class that has shown potent anti-inflammatory, analgesic and anti-reticulitis properties in various animal models. Tebufelone potently inhibits the formation of prostaglandins (PGE2) and blocks the formation of lipoxygenase pathway products [leukotriene (LTB4)] in rat macrophages (IC50 = 20 microM) and human whole blood (IC50 = 22 microM) in vitro. = 20 microM) and human whole blood (IC50 = 22 microM) from the formation of lipoxygenase pathway products [leukotriene (LTB4)] in vitro.
- $52
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
| Description | MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary arterial hypertension. MRE-269(ACT-333679) is an active metabolite of Selexipag (S253150). |
| Targets&IC50 | IP receptor (human):20 nM(Ki) |
| Alias | MRE269, MRE 269, ACT-333679 |
| Molecular Weight | 419.52 |
| Formula | C25H29N3O3 |
| Cas No. | 475085-57-5 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (131.1 mM)  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy MRE-269 | purchase MRE-269 | MRE-269 cost | order MRE-269 | MRE-269 chemical structure | MRE-269 formula | MRE-269 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.